000 01215 a2200337 4500
005 20250517040847.0
264 0 _c20160609
008 201606s 0 0 eng d
022 _a1759-4820
024 7 _a10.1038/nrurol.2015.149
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBeuselinck, Benoit
245 0 0 _aKidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?
_h[electronic resource]
260 _bNature reviews. Urology
_cAug 2015
300 _a424-6 p.
_bdigital
500 _aPublication Type: Journal Article; Comment
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aCarcinoma, Renal Cell
_xdrug therapy
650 0 4 _aCytochrome P-450 CYP3A
_xgenetics
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aIndoles
_xtherapeutic use
650 0 4 _aKidney Neoplasms
_xdrug therapy
650 0 4 _aMale
650 0 4 _aPolymorphism, Single Nucleotide
650 0 4 _aProtein Kinase Inhibitors
_xtherapeutic use
650 0 4 _aPyrroles
_xtherapeutic use
700 1 _aZucman-Rossi, Jessica
773 0 _tNature reviews. Urology
_gvol. 12
_gno. 8
_gp. 424-6
856 4 0 _uhttps://doi.org/10.1038/nrurol.2015.149
_zAvailable from publisher's website
999 _c25028431
_d25028431